Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Predicted Market Size Of The Bleeding Disorders Treatment Industry By 2029?
In recent times, the market size for treating bleeding disorders has seen noticeable expansion. It is projected to escalate from $16.95 billion in 2024 to $18.45 billion in 2025, with a compound annual growth rate (CAGR) of 8.9%. The growth during the historic period can be ascribed to heightened patient understanding, better access to healthcare, developments in hemophilia treatments, and worldwide market growth.
The market size of treatments for bleeding disorders is anticipated to experience robust expansion in the forthcoming years, rising to $25.93 billion in 2029 with a compound annual growth rate (CAGR) of 8.9%. The surge during the predicted period is linked to factors such as the elderly population, custom medications, patient support and advocacy, increased disposable income, and healthcare expenditure hike. Key trends during this projected timeframe consist of bespoke treatment strategies, the proliferation of telehealth facilities, progressive clotting factor therapies, RNA-oriented treatments, and ease of access to orphan drug recognition.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7843&type=smp
Which Factors Are Steering Growth In The Bleeding Disorders Treatment Market?
The growth of the bleeding disorders treatment market is predicted to surge due to the rise in the diagnosed cases of hemophilia. An inherited failure of the blood to clot correctly defines hemophilia. Its treatment revolves around replacement therapy, which replenishes the absent or deficient blood clotting factors with either recombinant forms of clotting factors VIII or IX or human plasma concentrates. For example, the Canada-based non-profit organization, the World Federation of Hemophilia (WFH), reported that, as of 2022, there were 257,146 recognized hemophilia patients globally, which included 208,957 with Hemophilia A and 42,203 with Hemophilia B. Hence, the surging number of identified hemophilia patients is a major driving factor for the expansion of the bleeding disorders treatment market.
Which Segment Accounts For The Largest Share In The Bleeding Disorders Treatment Market?
The bleeding disorders treatmentmarket covered in this report is segmented –
1) By Treatment: Desmopressin (DDAVP); Hormone Replacement Therapy; Contraceptives; Anti-Fibrinolytic or Clot-Stabilizing Drugs; Fibrin Sealants; Drugs Applied To Cuts; Pipeline Analysis
2) By Disease Type: Hemophilia A; Hemophilia B; Von Willebrand disease; Liver disease; Other Disease Types
3) By End User: Hospitals; Clinics; Specialty Clinics; Research Institutes; Other End Users
Subsegments:
1) By Desmopressin (DDAVP): Intravenous Formulations; Nasal Spray Formulations
2) By Hormone Replacement Therapy: Estrogen Therapy; Progesterone Therapy
3) By Contraceptives: Combined Oral Contraceptives; Progestin-Only Contraceptives
4) By Anti-Fibrinolytic or Clot-Stabilizing Drugs: Tranexamic Acid; Aminocaproic Acid
5) By Fibrin Sealants: Tisseel; Artiss
6) By Drugs Applied To Cuts: Antiseptics; Topical Hemostatic Agents
7) By Pipeline Analysis: Upcoming Treatments in Development; Novel Therapeutics and Technologies
Which Long-Term Trends Will Play A Crucial Role In The Bleeding Disorders Treatment Market?
Key players in the bleeding disorder treatment market are invested in creating cutting edge technologies like single-dose treatments. This innovation aims to improve not only the effectiveness of treatments but also patients’ quality of life by reducing dependence on continuous therapies. A single-dose treatment is a therapeutic method that provides the entire treatment in one dose, aiming for enduring effects without resorting to multiple doses. BioMarin Pharmaceutical Inc., a biotech firm based in the US, launched a manifestation of this approach in June 2023 with BioMarin’s ROCTAVIANTM (valoctocogene roxaparvovec-rvox). This specific therapy is designed for adults with severe hemophilia A—characterized by FVIII activity levels below 1 IU/dL—who lack pre-existing antibodies to adeno-associated virus serotype 5 (AAV5) as confirmed by an FDA-approved test.
Who Are The Dominant Players In The Bleeding Disorders Treatment Market Today?
Major companies operating in the bleeding disorders treatment market include AbbVie Inc., Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen Inc., CSL Behring Company, Grifols SA, Octapharma AG, BDI Pharma Inc., Ferring Pharmaceuticals Ltd., Xenetic Biosciences Inc., Sanofi SA, Alnylam Pharmaceuticals Inc., Novartis AG, Shire plc, Novo Nordisk, Grifols SA, F. Hoffmann-La Roche AG, Sanofi Corporation, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Biotest AG, LFB S.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., HEMA Biologics LLC, ADMA Biologics Inc., Grifols Biologicals Inc., Octapharma Plasma Inc., Kedrion Biopharma Inc., BPL Plasma Inc., BioLife Plasma Services, CSL Plasma Ltd., Grifols Shared Services North America Inc., Octapharma USA Inc., Shire US Inc., Pfizer Canada Inc., Grifols Canada Ltd., Octapharma Canada Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report
What Regional Factors Are Accelerating Growth In The Bleeding Disorders Treatment Market?
North America was the largest region in the bleeding disorders treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorders treatment market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=7843&type=smp
Browse Through More Reports Similar to the Global Bleeding Disorders Treatment Market 2025, By The Business Research Company
Wearable Blood Pressure Monitors Global Market Report 2025
Patient Blood Management Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report
Conjugated Monoclonal Antibodie Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
